Back to Search Start Over

XAF1 is secreted from stressed tumor cells to activate T cell-mediated tumor surveillance via Lck-ERK signaling.

Authors :
Ahn J
Jang SH
Jang S
Yoon JH
Lee MG
Chi SG
Source :
Neoplasia (New York, N.Y.) [Neoplasia] 2025 Jan; Vol. 59, pp. 101094. Date of Electronic Publication: 2024 Nov 29.
Publication Year :
2025

Abstract

X-linked inhibitor of apoptosis-associated factor 1 (XAF1) is a stress-inducible tumor suppressor that is commonly inactivated in multiple types of human malignancies. Nevertheless, the molecular basis for the XAF1-mediated tumor suppression remains largely undefined. Here, we report that XAF1 is secreted from cells under various cytotoxic stress conditions and activates T cell-mediated tumor surveillance. In cancer cells exposed to interferon -γ, tumor necrosis factor -α, and etoposide, XAF1 is elevated and actively secreted through the unconventional endo-lysosomal trafficking pathway and the zinc finger 4 domain of XAF1 plays an essential for this secretion. Secreted XAF1 is internalized into nearby T cells through clathrin-mediated endocytosis and stimulates proliferation, migration, and tumor infiltration of T cells. Internalized XAF1 activates RAF-MEK-ERK signaling through the direct interaction with and phosphorylation of lymphocyte-specific protein tyrosine kinase. In response to interferon -γ injection, Xaf1 <superscript>+</superscript> <superscript>/+</superscript> tumors display significantly higher regression rate and T cell infiltration compared to Xaf1 <superscript>-/-</superscript> tumors while Xaf1 <superscript>-/-</superscript> tumors are markedly reduced by injection of recombinant Xaf1. XAF1 expression is associated with overall survival in T cell-enriched cancer patients and also correlates with prognosis in T cell-based immunotherapies. Together, our study identifies XAF1 as a novel secretory immune-modulatory tumor suppressor, illuminating the mechanistic consequence of its inactivation in tumorigenesis.<br />Competing Interests: Declaration of competing interest The authors declare that they have no conflict of interest.<br /> (Copyright © 2024. Published by Elsevier Inc.)

Details

Language :
English
ISSN :
1476-5586
Volume :
59
Database :
MEDLINE
Journal :
Neoplasia (New York, N.Y.)
Publication Type :
Academic Journal
Accession number :
39615106
Full Text :
https://doi.org/10.1016/j.neo.2024.101094